Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption

Inbal Braunstein; Tara C Gangadhar; Rosalie Elenitsas; Emily Y Chu

doi:10.1111/cup.12318

Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption

J Cutan Pathol. 2014 Jun;41(6):539-43. doi: 10.1111/cup.12318. Epub 2014 Mar 11.

Authors

Inbal Braunstein¹, Tara C Gangadhar, Rosalie Elenitsas, Emily Y Chu

Affiliation

¹ Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, MD, USA.

PMID: 24517243
DOI: 10.1111/cup.12318

Abstract

Vemurafenib is a specific inhibitor of the V600E mutated BRAF protein kinase used for the treatment of unresectable or metastatic melanoma harboring this mutation. Multiple predictable side effects have been described with use of this targeted therapy, and implicate BRAF and mitogen activated protein kinase (MAPK) signaling pathways in their pathogenesis. Herein, we report the novel finding of an interface dermatitis in radiation recall and a keratosis pilaris-like clinical reaction in a patient treated with vemurafenib.

Keywords: dermatopathology; melanoma; radiation therapy.

Publication types

Case Reports

MeSH terms

Abnormalities, Multiple / chemically induced*
Abnormalities, Multiple / pathology
Adult
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Darier Disease / chemically induced*
Darier Disease / pathology
Drug Eruptions / pathology*
Eyebrows / abnormalities*
Eyebrows / pathology
Humans
Indoles / adverse effects*
Indoles / therapeutic use
Male
Melanoma / drug therapy*
Melanoma / pathology
Melanoma / surgery
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology
Skin Neoplasms / surgery
Sulfonamides / adverse effects*
Sulfonamides / therapeutic use
Vemurafenib

Substances

Antineoplastic Agents
Indoles
Sulfonamides
Vemurafenib

Supplementary concepts

Burnett Schwartz Berberian syndrome